About
Montis Biosciences is a biotechnology company developing dual-mechanism antibodies targeting complement C1q to treat neuroinflammatory, autoimmune, neurodegenerative, and ophthalmic diseases, with a lead program focused on Guillain-Barré syndrome.
Explore Montis Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.